Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia

Leukemia & Lymphoma
M A SarmientoR M Bengió

Abstract

A 68-year-old man, with Hairy Cell Leukemia developed a Guillain-Barré syndrome (G-B), 32 days after a single course of 2-Chlorodeoxyadenosine (CDA) at 0,14 mg/k/d, for five days in a two-hour-i.v. infusion and following a febrile neutropenia episode. In order to clarify whether this G-B case was related to an infection or to CDA neurotoxicity, we screened for infection-related autoimmune G-B and for antibodies (abs.) against gangliosides of peripheral nerves. Blood and urinary cultures were negative as well as serum anti-virus abs. However, serum anti-ganglioside abs. were positive for anti-asialo GM1 and anti-Gd1b. This latter finding was consistent with an autoimmune mechanism, not described until now as CDA neurotoxicity. In the present case, we do not have enough evidence to link CDA administration to the G-B syndrome. We think that it is necessary to exclude other causes of neurotoxicity before considering CDA adverse effect.

References

Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonJ M Sorensen
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro

❮ Previous
Next ❯

Citations

May 10, 2007·Leukemia & Lymphoma·Atilla OzkanRidvan Ali
Mar 21, 2003·Leukemia·A AlexopoulouT Kalmantis

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

British Journal of Haematology
A R PettittJ C Cawley
Lancet
Richard A C Hughes, David R Cornblath
Annals of Oncology : Official Journal of the European Society for Medical Oncology
A von RohrSwiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G JuliussonG Tjønnfjord
© 2021 Meta ULC. All rights reserved